Literature DB >> 18329536

Fibrosis in systemic sclerosis.

John A Varga1, Maria Trojanowska.   

Abstract

This article reviews current understanding of the pathophysiology of fibrosis in systemic sclerosis. It highlights recent discoveries, insights, and emerging research, and potential opportunities for the development of targeted antifibrotic therapies.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18329536     DOI： 10.1016/j.rdc.2007.11.002

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN： 0889-857X            Impact factor:   2.670


  28 in total

Review 1.  The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis.

Authors:  Yoshihide Asano; Andreea M Bujor; Maria Trojanowska
Journal:  J Dermatol Sci       Date:  2010-07-03       Impact factor: 4.563

Review 2.  Recent advances in the treatment of systemic sclerosis.

Authors:  Vasiliki Kalliopi K Bournia; Panayiotis G Vlachoyiannopoulos; Carlo Selmi; Haralampos M Moutsopoulos; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

3.  Enrichment of Scleroderma Vascular Disease-Associated Autoantigens in Endothelial Lineage Cells.

Authors:  Zsuzsanna H McMahan; Tricia R Cottrell; Fredrick M Wigley; Brendan Antiochos; Elias T Zambidis; Tea Soon Park; Marc K Halushka; Laura Gutierrez-Alamillo; Raffaello Cimbro; Antony Rosen; Livia Casciola-Rosen
Journal:  Arthritis Rheumatol       Date:  2016-10       Impact factor: 10.995

4.  Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy.

Authors:  Jun Wei; Swati Bhattacharyya; Warren G Tourtellotte; John Varga
Journal:  Autoimmun Rev       Date:  2010-09-21       Impact factor: 9.754

5.  Endothelial cells recruit macrophages and contribute to a fibrotic milieu in bleomycin lung injury.

Authors:  Heather G Leach; Izabela Chrobak; Rong Han; Maria Trojanowska
Journal:  Am J Respir Cell Mol Biol       Date:  2013-12       Impact factor: 6.914

6.  Assessment of tissue fibrosis in skin biopsies from patients with systemic sclerosis employing confocal laser scanning microscopy: an objective outcome measure for clinical trials?

Authors:  Joanna Busquets; Francesco Del Galdo; Eugene Y Kissin; Sergio A Jimenez
Journal:  Rheumatology (Oxford)       Date:  2010-03-04       Impact factor: 7.580

7.  Increased expression of NAPDH oxidase 4 in systemic sclerosis dermal fibroblasts: regulation by transforming growth factor β.

Authors:  Sonsoles Piera-Velazquez; Alma Makul; Sergio A Jiménez
Journal:  Arthritis Rheumatol       Date:  2015-10       Impact factor: 10.995

8.  Transcriptional regulation of matrix metalloproteinase-1 and collagen 1A2 explains the anti-fibrotic effect exerted by proteasome inhibition in human dermal fibroblasts.

Authors:  Laurence Goffin; Queralt Seguin-Estévez; Montserrat Alvarez; Walter Reith; Carlo Chizzolini
Journal:  Arthritis Res Ther       Date:  2010-04-29       Impact factor: 5.156

Review 9.  Noncanonical transforming growth factor beta signaling in scleroderma fibrosis.

Authors:  Maria Trojanowska
Journal:  Curr Opin Rheumatol       Date:  2009-11       Impact factor: 5.006

10.  Regulatory T cells in skin are uniquely poised to suppress profibrotic immune responses.

Authors:  Lokesh A Kalekar; Jarish N Cohen; Nicolas Prevel; Priscila Muñoz Sandoval; Anubhav N Mathur; Joshua M Moreau; Margaret M Lowe; Audrey Nosbaum; Paul J Wolters; Anna Haemel; Francesco Boin; Michael D Rosenblum
Journal:  Sci Immunol       Date:  2019-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.